The stock of Seres Therapeutics Inc (MCRB) has gone up by 12.27% for the week, with a 13.17% rise in the past month and a -40.96% drop in the past quarter. The volatility ratio for the week is 7.30%, and the volatility levels for the past 30 days are 4.96% for MCRB. The simple moving average for the past 20 days is 11.70% for MCRB’s stock, with a -40.89% simple moving average for the past 200 days.
Is It Worth Investing in Seres Therapeutics Inc (NASDAQ: MCRB) Right Now?
MCRB has 36-month beta value of 2.62. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for MCRB is 6.44M, and currently, short sellers hold a 11.04% ratio of that float. The average trading volume of MCRB on June 25, 2025 was 96.63K shares.
MCRB) stock’s latest price update
Seres Therapeutics Inc (NASDAQ: MCRB)’s stock price has soared by 106377 in relation to previous closing price of 7.42. Nevertheless, the company has seen a gain of 12.27% in its stock price over the last five trading days. globenewswire.com reported 2025-05-27 that Results highlight potential role of SER-155 in promoting peripheral T-cell recovery and immune reconstitution to support favorable outcomes post allogeneic hematopoietic stem cell transplant (allo-HSCT) Results highlight potential role of SER-155 in promoting peripheral T-cell recovery and immune reconstitution to support favorable outcomes post allogeneic hematopoietic stem cell transplant (allo-HSCT)
Analysts’ Opinion of MCRB
Many brokerage firms have already submitted their reports for MCRB stocks, with Chardan Capital Markets repeating the rating for MCRB by listing it as a “Neutral.” The predicted price for MCRB in the upcoming period, according to Chardan Capital Markets is $6 based on the research report published on May 08, 2025 of the current year 2025.
Oppenheimer gave a rating of “Outperform” to MCRB, setting the target price at $12 in the report published on June 26th of the previous year.
MCRB Trading at 3.05% from the 50-Day Moving Average
After a stumble in the market that brought MCRB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.48% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MCRB starting from Young Teresa L., who sale 63 shares at the price of $7.28 back on May 16 ’25. After this action, Young Teresa L. now owns 5,044 shares of Seres Therapeutics Inc, valued at $459 using the latest closing price.
Shaff Eric D., the CEO and President of Seres Therapeutics Inc, sale 220 shares at $7.28 during a trade that took place back on May 16 ’25, which means that Shaff Eric D. is holding 10,102 shares at $1,602 based on the most recent closing price.
Stock Fundamentals for MCRB
The total capital return value is set at -0.88. Equity return is now at value -3758.21, with -26.46 for asset returns.
Based on Seres Therapeutics Inc (MCRB), the company’s capital structure generated 0.64 points at debt to capital in total, while cash flow to debt ratio is standing at -0.97. The debt to equity ratio resting at 1.77. The interest coverage ratio of the stock is -33.82.
Currently, EBITDA for the company is -121.31 million with net debt to EBITDA at -0.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.11.
Conclusion
To put it simply, Seres Therapeutics Inc (MCRB) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
